AstraZeneca announced that the company has submitted applications in the European Union (EU) for once-daily SEROQUEL XR™ (quetiapine fumarate) Extended-Release Tablets (quetiapine XR), seeking approval for the treatment of major depressive disorder (MDD) including maintenance therapy in adult patients using Mutual Recognition Procedure (MRP). This follows an sNDA submission for SEROQUEL XR in MDD in Read the rest of this entry »
Erectile dysfunction is always a matter of the heart, but new research shows that more than romance is at stake. Two new studies of men with type 2 diabetes found that erectile dysfunction (ED) was a powerful early warning sign for serious heart disease, including heart attack and death.
One of the studies also showed that cholesterol-lowering Read the rest of this entry »
The U.S. Food and Drug Administration requested that SEI Pharmaceuticals, of Miami, Fla., recall all Xiadafil VIP Tabs sold in 8 tablet bottles (Lot # 6K029) or blister cards of 2 tablets (Lot # 6K029-SEI) because these products contain a potentially harmful, undeclared ingredient that may dangerously affect a person’s blood pressure and can cause other life-threatening side effects. These lots of Xiadafil Read the rest of this entry »